Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019
Mitotic rate as an important prognostic factor in cutaneous malignant melanoma.
Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Cytotoxicity and apoptotic effects of the ethyl acetate fraction ofContemporary oncology (Poznan, Poland) · 2025Article
- The Prognostic Value of Proliferative Activity in Cutaneous Melanoma: A Pilot Study Evaluating the Mitotic Rate and Ki67 Index to Predict Patient Outcomes.Biomedicines · 2024Article
- Integrating Spatial and Morphological Characteristics into Melanoma Prognosis: A Computational Approach.Cancers · 2024Article
- Article
- Article
- BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study.Turk patoloji dergisi · 2023Article
- The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients.Medicine and pharmacy reports · 2022Review
- Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas.Frontiers in oncology · 2022Article
- Article
- Genetic variants of SDCCAG8 and MAGI2 in mitosis-related pathway genes are independent predictors of cutaneous melanoma-specific survival.Cancer science · 2021Article
- Article
- Prognostic significance of regression and mitotic rate in head and neck cutaneous melanoma.Laryngoscope investigative otolaryngology · 2021Article
- Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundRecently, the quantification of mitoses in cutaneous melanoma has been discharged from the main prognostic variables of the TNM classification.
objectiveTo investigate the prognostic value of the presence of mitoses in primary cutaneous melanoma and to establish the number of mitoses per mm
methodsA retrospective observational study was performed on 141 patients treated for cutaneous melanoma, who were assessed by the same pathologist, and who had a minimum follow-up of 2 years. Clinical, epidemiological, histopathological and follow-up variables were gathered and compared with the number of mitoses to distinguish the significance of differences by means of univariate, multivariate, and survival analyses.
resultsThe cut-off level related to a better sensitivity and specificity was 1.50 mitoses per mm
conclusionsA mitotic rate of two or more mitoses per mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.